Kenvue Inc. $KVUE Shares Sold by Kapitalo Investimentos Ltda

Kapitalo Investimentos Ltda cut its stake in shares of Kenvue Inc. (NYSE:KVUE) by 97.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 56,000 shares of the company’s stock after selling 1,944,000 shares during the quarter. Kapitalo Investimentos Ltda’s holdings in Kenvue were worth $965,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of KVUE. Physician Wealth Advisors Inc. lifted its holdings in shares of Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares during the last quarter. Elyxium Wealth LLC acquired a new position in shares of Kenvue in the 4th quarter valued at $26,000. MV Capital Management Inc. acquired a new stake in Kenvue during the 4th quarter worth about $28,000. Reflection Asset Management acquired a new stake in Kenvue during the 4th quarter worth about $32,000. Finally, SBI Securities Co. Ltd. lifted its stake in Kenvue by 82.4% during the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after buying an additional 1,027 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.59% of the company’s stock.

Kenvue Trading Up 0.1%

Shares of NYSE KVUE opened at $19.00 on Tuesday. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a one year low of $14.02 and a one year high of $22.87. The business has a 50-day moving average price of $18.23 and a two-hundred day moving average price of $17.87. The firm has a market capitalization of $36.47 billion, a PE ratio of 22.35, a PEG ratio of 1.44 and a beta of 0.47.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The company had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The firm’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.24 EPS. As a group, analysts predict that Kenvue Inc. will post 1.16 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were paid a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.4%. The ex-dividend date was Wednesday, May 13th. Kenvue’s dividend payout ratio is currently 97.65%.

Analyst Upgrades and Downgrades

Several brokerages have commented on KVUE. Zacks Research cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Wall Street Zen upgraded shares of Kenvue to a “buy” rating in a research report on Sunday, July 12th. UBS Group raised their price objective on shares of Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday. Finally, Citigroup lowered their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 15th. Three analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $19.50.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.